CStone Pharmaceuticals, a biotechnology company, has enrolled and dosed its first patient in a phase one clinical trial in China for the recombinant humanised anti-programmed death-1 monoclonal antibody, CS1003, it is reported today.
This multi-centre Phase one clinical trial is evaluating the safety, tolerability and preliminary anti-tumour activity of CS1003 in Chinese patients with advanced cancers, led by the Beijing Cancer Hospital.
Dr Frank Jiang, chairman and CEO of CStone, said, 'CS1003 is an important IO backbone in CStone's pipeline and together with our PD-L1 monoclonal antibody (CS1001), is essential to our combination therapy strategy. We are happy to see Phase I trial get under way in China. We plan to carry out global development for this promising drug candidate as monotherapy and in combination with internal and external therapies to benefit cancer patients in China and globally.'
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886